KAI-7535, a once-daily injectable small-molecule GLP-1, will receive a $50 million boost following the IPO. Hengrui has ...

Retractable Technologies, the maker of a retractable needle and other safety medical products, is cutting roughly 16% of its ...

Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...

An FDA review of records in the U.S. clinical trials database shows that results have not been reported for 30% of clinical ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals. | With its latest obesity play appearing to pay off, Regeneron has turned its attention ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...

Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets. | Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...